Participation of the AngII/TRPC6/NFAT axis in the pathogenesis of podocyte injury in rats with type 2 diabetes

RUIXIA MA1, YAN XU1, HANYAN ZHOU1, DI ZHANG2, DANDAN YAO1, LIMIN SONG2 and YUAN LIU2

1Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000; 2Department of Special Medicine, School of Medicine, Qingdao University, Qingdao, Shandong 266071, P.R. China

Received April 21, 2018; Accepted December 19, 2018

DOI: 10.3892/mmr.2019.9871

Abstract. The canonical transient receptor potential channel 6 ion channel is expressed in podocytes and is an important component of the glomerular slit diaphragm. Focal segmental glomerulosclerosis is closely associated with TRPC6 gene mutations, and TRPC6 mediates podocyte injury induced by high glucose. Angiotensin II (AngII) has been revealed to enhance TRPC6 currents in certain types of cells, including podocytes and ventricular myocytes. It has been reported that glucose regulated TRPC6 expression in an AngII-dependent manner in podocytes and that this pathway is critical in diabetic nephropathy. In the present study, the role of TRPC6 detected by western blotting and reverse transcription-quantitative polymerase chain reaction in AngII-mediated podocyte injury was evaluated in rats with type 2 diabetes induced by high-calorie diets and streptozotocin. The results demonstrated that urinary albumin excretion was elevated, and morphological changes, including glomerular basement membrane thickening and podocyte process effacement, were observed. There was increased expression of AngII and TRPC6 in diabetic rats. The angiotensin receptor blocker valsartan significantly reduced TRPC6 and nuclear factor of activated T-cells (NFAT) overexpression in diabetic rats. These results in vivo were confirmed by studies in vitro, which demonstrated that inhibition of TRPC6 ameliorated high glucose-induced podocyte injury by decreasing NFAT mRNA levels. Taken together, the present results suggested that the AngII/TRPC6/NFAT axis may be a crucial signaling pathway in podocytes that is necessary for maintaining the integrity of the glomerular filtration barrier. In addition, TRPC6 may represent a potential therapeutic target for diabetic nephropathy.

Introduction

Diabetic nephropathy has become the leading cause of end-stage renal disease worldwide, developing in ~40% of patients with type 2 diabetes as glomerular function progressively declines. The glomerular filtration barrier consists of three main elements: Capillary endothelium, glomerular basement membrane (GBM) and a population of specialized cells (podocytes). In type 2 diabetes, mesangial expansion and GBM thickening are characteristics of renal dysfunction (1-3). In addition, alterations in podocyte structure, number and density are present at the onset of diabetic nephropathy (4,5). In addition, podocyte effacement appears to contribute to microalbuminuria and to the pathogenesis of diabetic nephropathy (6-8).

Transient receptor potential (TRP) channels are a family of nonselective Ca2+-permeable cation channels that are widely expressed in vertebrate tissues. In particular, TRP channel 6 (TRPC6) expression and function have been studied in several tissues (9), including brain, kidney and heart (10-12). TRPC6 has been shown to serve an important role in the regulation of podocyte structure and function (13). Gain-of-function mutations in the TRPC6 gene resulted in hereditary focal segmental glomerulosclerosis (14), which is characterized by proteinuria, progressive renal failure and glomerular lesions. In addition, TRPC6 overexpression, which is associated with actin cytoskeleton rearrangement in podocytes, is a common feature of human proteinuric kidney diseases (10). TRPC6 knockdown by small interfering RNA (siRNA) attenuated high glucose-induced podocyte apoptosis, which contributes to the development of diabetic nephropathy (15). Sonneveld et al (16) reported that TRPC6 expression in podocytes was regulated by glucose in an Angiotensin II (AngII)-dependent manner (17). Taken together, these results suggested that TRPC6 is a potential therapeutic target for diabetic nephropathy. High glucose levels in diabetes increases AngII expression in glomeruli, especially in mesangial cells (18,19). Ang-converting enzyme inhibitors and AngII receptor blockers (ARBs) have been shown to attenuate progressive glomerulosclerosis in several disease models (20-22). The ARB candesartan lowered the peak level of proteinuria by decreasing the expression of functional molecules in the slit diaphragm and slowed the progression of diabetic renal disease (17,23). A recent study demonstrated that AngII perpetuated podocyte injury via...
the persistent activation of Notch1 and Snail signaling (24). These results demonstrate that AngII participates in mediating the effects of hyperglycemia in the progression of diabetic nephropathy (25).

Numerous studies have provided evidence for the involvement of AngII in the regulation of TRPC6. For example, AngII increased TRPC6 expression and activated TRPC6 currents in non-renal cells, including mesenteric artery myocytes and ventricular myocytes (26,27). Accordingly, currents evoked by AngII in glomerular podocytes were eliminated by transfection with siRNA against TRPC6 (28). Increased TRPC6 expression in the podocyte membrane mediated apoptosis induced by AngII and albumin overload (29,30). TRPC6 also participated in the AngII-induced activation of nuclear factor in activated T cells (NFAT), contributing to the progression of cardiac hypertrophy (13). TRPC6-induced activation of the NFAT signaling pathway was identified as a potential mediator of focal segmental glomerulosclerosis (31). Furthermore, TRPC6-mediated Ca\textsuperscript{2+} influx and activation of Ca\textsuperscript{2+}-dependent protein phosphatase calcineurin and its substrate NFAT have been implicated in nephropathy induced by doxorubicin and AngII (32). Nevertheless, it remains unclear as to whether AngII mediates podocyte changes associated with type 2 diabetic nephropathy via TRPC6.

It was hypothesized that high glucose levels result in podocye injury through the activation of a pathway mediated by AngII, TRPC6 and NFAT. In the present study, it was revealed that increased AngII expression in glomerular podocytes was accompanied by enhanced urinary albumin excretion in a rat model of a high-calorie diet and streptozocin-induced type 2 diabetes. The ARB valsartan ameliorated diabetic podocyte injury via the downregulation of TRPC6 and NFAT. The results of the in vitro studies supported the role of TRPC6 and NFAT in AngII-induced podocyte injury.

Materials and methods

Animals. Pathogen-free male Wistar rats (n=50; 8-week-old; 200 g) were obtained from the Institute of Drug Control (Qingdao, China). The rats were housed in individual cages in a temperature-controlled room with a 12-h light/dark cycle at 50-60% relative humidity and were given food and water ad libitum. The rats were allowed to acclimatize for 2 weeks prior to the dietary intervention. Protocols for the animal experiments were approved by the Qingdao University Animal Care and Use Committee (Shandong, China) and were developed in accordance with guidelines set by the National Institutes of Health Guide for Care and Use of Laboratory Animals. The present study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University.

The rat model of type 2 diabetes was generated according to a previously described method (33). The rats were randomly divided into two groups according to diet: Regular rat chow (n=10; normal control group) or high-calorie diet (n=40; 10% animal fat, 20% cane sugar, 2.5% cholesterol, 1% cholate and 66.5% regular chow). Following 8 weeks, rats fed the high-calorie diet were intraperitoneally injected with 30 mg/kg\textsuperscript{3} streptozocin to induce type 2 diabetes. One week later, fasting blood glucose and insulin levels were measured, and the insulin sensitivity index was calculated as 22.5/[fasting blood glucose (FBG) x insulin (INS)]. Rats with fasting blood glucose levels >10.0 mmol\textsuperscript{-1} and higher insulin levels (n=40) were further subdivided into two groups: The ARB treatment group (n=20) receiving valsartan (40 mg/kg/day given orally; Novartis International AG, Basel, Switzerland), and the diabetes mellitus (DM) control group (n=20) receiving normal saline. These treatments were administered once a day for 12 weeks.

Following the 12-week treatment, the rats were weighed and urine samples were collected. The rats were then sacrificed, blood samples were obtained, and the kidneys were collected and weighed.

Determination of urinary albumin and creatinine concentrations. To evaluate albumin and creatinine excretion, 24-h urine samples were collected from the rats every 2 weeks during the 12-week treatment period. Albumin was measured using a turbidimetric immunoassay kit (Shibayagi Co., Ltd., Shibukawa, Japan). Creatinine was measured using an automatic biochemistry analyzer (model no. 7600-020; Hitachi, Ltd., Tokyo, Japan).

Evaluation of metabolic parameters. Blood samples were obtained from the tail vein once per week. FBG was determined using a glucometer (OneTouch\textsuperscript{TM}SureStep\textsuperscript{TM}; LifeScan, Inc., Milpitas, CA, USA). Serum insulin levels and glycated hemoglobin (HbAlc) levels were determined by enzyme-linked immunosorbent assay (cat. nos. YJ-58700 and YJ-0021a, Aquatic Diagnostic Ltd., Stirling, Scotland).

Serum creatinine, urea nitrogen, total cholesterol, triglyceride, low-density lipoprotein and high-density lipoprotein levels were determined using an automatic biochemistry analyzer. Creatinine clearance was calculated using the following formula: Creatinine clearance=urine creatinine concentration/serum creatinine concentration x volume of urine (ml) per min].

Noninvasive blood pressure measurement. Blood pressure was measured using a tail cuff system (model LE5002; Diagnostic Systems Laboratories, Webster, TX, USA) in conscious rats, while animals rested in a climate-controlled room (23°C). Systolic blood pressure was measured five times consecutively.

Glomerular morphological characteristics. Morphological characteristics of 50-nm renal cortex sections, including GBM thickness and the condition of podocyte processes, were examined and photographed using a JEM-1200 transmission electron microscope (JEOL, Ltd., Tokyo, Japan).

Cell culture. A conditionally immortalized mouse podocyte cell line, MPC5, was donated by The Central Laboratory of Shandong University (Shandong, China), and was cultured as previously described (34). The cell density at 60% were grown on plates in RPMI-1640 medium supplemented with 10% fetal bovine serum (cat. no. 1213G057, Beijing Solarbio Science & Technology Co., Ltd., Beijing, China), 10-50 U/ml recombinant mouse γ-interferon (IFN), 100 U/ml penicillin and 100 mg/ml streptomycin at 33°C under a humidified atmosphere containing 5% CO\textsubscript{2}. Then the conditions were changed to 37°C (without γ-IFN) to induce cell differentiation.
into mature podocytes and cells were cultured for 10-14 days. Differentiated podocytes were then divided into five groups: Normal glucose (NG) group (5.6 mmol/l), high glucose (HG) group (30 mmol/l), high mannitol group (NG + mannitol 25 mmol/l), the valsartan (VAL) group (HG + the AngII receptor blocker VAR, 10^{-3} mmol/l), and HS group (HG + the TRP channel inhibitor (35), SAR7334, 1 μM) cultured in 37°C for 48 h.

Western blot analysis. Cultured podocytes or homogenized renal tissue were lysed in cold cell lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM ethylene diamine tetraacetic acid and 1% Triton X-100) containing protease and phosphatase inhibitors. BCA protein assay kit (P0012, Beyotime Institute of Biotechnology, Haimen, China) and microplate reader (MD-SpectraMax, M5, USA) was used to determine total protein concentrations according to specification's instruction. The quantity of protein loaded per lane was 35 g/10 l. The proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membranes. Membranes were blocked with 3% nonfat dry milk for 2 h at room temperature. Primary antibodies against TRPC6 (sc-19196, goat anti-rat; 1:500), NFAT (sc-7296, mouse anti-rat; 1:2,000) and AngII (sc-20718, rabbit anti-rat; 1:1,000) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and incubated at 4°C overnight. Horseradish peroxidase-conjugated anti-immunoglobulin G served as the secondary antibody (ZB-2301, 1:5,000, Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc., Beijing, China) and incubated at room temperature for 1 h, and proteins were detected using an enhanced chemiluminescence kit (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.; OriGene Technologies, Inc., Beijing, China) and measured by densitometric scanning. Progress was calibrated against a standard protein ladder to account for loading variations.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from kidney cortex samples and cultured podocytes using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The RNA was analyzed by 0.6% agarose gel electrophoresis, visualized by ethidium bromide and was quantified by spectrometry. Complementary cDNA was synthesized using PrimeScript RT Reagent Kit (cat. no. DRR037A; Takara Biotechnology Co., Ltd., Dalian, China). RT reactions were for 55 min at 25°C, 5 min at 85°C and then held at 4°C for 1 h. RT-qPCR was carried out using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) on an ABI PRISM 7000 HT (cat. no. 11744-100; Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Sequences of primers targeting TRPC6, AngII, and NFAT2 are shown in Table I. Reactions were incubated at 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec, 60°C for 30 sec and 72°C for 40 sec, followed by melting curve analysis. Relative gene expression was performed using the comparative Cq method (\(2^{-\Delta\Delta Cq}\)) (36) with GAPDH as the internal control.

Statistical analysis. Results were expressed as the mean ± standard deviation of at least three independent experiments. Group differences were compared by one-way analysis of variance followed by Student-Newman-Keuls post hoc test. P<0.05 was considered to indicate a statistically significant difference. Least significant different t-test was used for pairwise comparison, while Tamhane's T2 was used for Heteroscedasticity. All analyses were performed using SPSS software (version 22; IBM Corp., Armonk, IL, USA).

Results

Evaluation of metabolic parameters. The present study measured the metabolic parameters of rats in the normal control, DM and ARB treatment groups (n=10 per group). The results revealed that there was a lower insulin sensitivity index, and increased levels of FBG, HbA1c and lipids in the DM group than in the normal controls (Table II). However, fasting insulin and serum creatinine levels did not differ between the groups. In addition, no significant differences in metabolic parameters were observed between the DM and ARB treatment groups (Table II).

Kidney function parameters. To assess glomerular injury, the present study measured urinary albumin excretion and found a significant difference between the DM and normal control groups. However, the ARB VAL significantly decreased urinary albumin excretion in the diabetic rats following 8 weeks of treatment (Fig. 1A). ARB treatment also decreased the elevated kidney weight/body weight ratio observed in diabetic rats (Fig. 1B) but did not affect creatinine clearance or systolic blood pressure (Fig. 1C and D).

AngII expression in glomerular podocytes and podocyte lesions in type 2 diabetic nephropathy. To better understand the role of AngII in podocytes, the present study analyzed AngII expression changes in the glomerular podocytes of type 2 diabetic rats via western blotting and qPCR. In addition, the effects of ARB treatment on GBM thickness and podocyte effacement were examined by electron microscopy. In the DM group, the mRNA and protein levels of AngII were significantly higher than those of the normal control group (Fig. 2A and B); however, treatment with VAL (40 mg/kg/day for 12 weeks) decreased AngII expression to levels almost equivalent to those of the normal controls. In DM rats, diabetic nephropathy was observed, which manifested as GBM thickening and podocyte process effacement (Fig. 2C). In addition, impairment of the glomerular filtration barrier was ameliorated by ARB treatment (Fig. 2).

Involvement of TRPC6 and NFAT in AngII-induced podocyte injury. To determine whether TRPC6 and NFAT were involved in AngII-induced podocyte injury in type 2 diabetes, the present study evaluated the expression of TRPC6 and NFAT in the rat model employed. The results revealed higher mRNA and protein levels of TRPC6 and NFAT in diabetic rats when compared with the normal controls (Fig. 3). These changes were attenuated by ARB treatment (Fig. 3).

ARB treatment attenuates HG-induced upregulation of AngII, TRPC6, and NFAT in vitro. As the results of the present study thus far suggested that the effects of AngII in the pathogenesis
of diabetic nephropathy were mediated by TRPC6/NFAT signaling, the present study then investigated whether this pathway was activated by HG levels in cultured podocytes. The protein levels (Fig. 4A-C) and mRNA levels (Fig. 4D-F) of AngII, TRPC6, and NFAT were markedly higher in cells exposed to HG (30 mmol/l) for 48 h when compared with cells exposed to NG levels (5.6 mmol/l). This effect was significantly attenuated by ARB treatment with VAL. Cells cultured with 5.6 mmol/l glucose and 25 mmol/l mannitol were also evaluated. The expression of AngII, TRPC6 and NFAT in these cells was similar to that of the NG control group, thereby ruling out the osmotic effect of glucose.

Table I. Primers used in the in vitro and in vivo studies.

A. In vitro studies using mouse podocytes

<table>
<thead>
<tr>
<th>GenBank accession no.</th>
<th>Gene</th>
<th>Sequence (5'-3')</th>
<th>Length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM_001282086.1</td>
<td>TRPC6 (F)</td>
<td>TCTCTGGTTTACGGCAGCAGA</td>
<td>228</td>
</tr>
<tr>
<td>NM_001282086.1</td>
<td>TRPC6 (R)</td>
<td>GGAGCTTTGGCTGCTTATTCA</td>
<td>185</td>
</tr>
<tr>
<td>NM_00164109.1</td>
<td>NFAT2 (F)</td>
<td>GGTGCCCTTTTCGCGACGTA</td>
<td>90</td>
</tr>
<tr>
<td>NM_00164109.1</td>
<td>NFAT2 (R)</td>
<td>TGAGCCCTTTGTGGTGAAGACTTG</td>
<td></td>
</tr>
<tr>
<td>NM_001161731.2</td>
<td>AngII (F)</td>
<td>ACTGCGAAATATGATGTTGAA</td>
<td></td>
</tr>
<tr>
<td>NM_001161731.2</td>
<td>AngII (R)</td>
<td>CTTTGGATTTCTGGTTGTGTC</td>
<td></td>
</tr>
<tr>
<td>NM_001289726.1</td>
<td>GAPDH (F)</td>
<td>CTCAATGACCCACAGTCCATGC</td>
<td>201</td>
</tr>
<tr>
<td>NM_001289726.1</td>
<td>GAPDH (R)</td>
<td>CACATTGGGAGGTAGGAACAC</td>
<td></td>
</tr>
</tbody>
</table>

B. In vivo studies in rats

<table>
<thead>
<tr>
<th>GenBank accession no.</th>
<th>Gene</th>
<th>Sequence (5'-3')</th>
<th>Length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM_0053559.1</td>
<td>TRPC6 (F)</td>
<td>TACGGATTTGGGAGCTATTCT</td>
<td>98</td>
</tr>
<tr>
<td>NM_0053559.1</td>
<td>TRPC6 (R)</td>
<td>AAAGTCATTTCTGGGAGTCA</td>
<td></td>
</tr>
<tr>
<td>NM_001244933.1</td>
<td>NFAT2 (F)</td>
<td>GAGGGAAGAAGATGTTGTC</td>
<td>125</td>
</tr>
<tr>
<td>NM_001244933.1</td>
<td>NFAT2 (R)</td>
<td>GCACAGTCTCGGTCTGTT</td>
<td></td>
</tr>
<tr>
<td>NM_001006992.1</td>
<td>AngII (F)</td>
<td>GCAAGCTACAGGAGGTCTC</td>
<td>88</td>
</tr>
<tr>
<td>NM_001006992.1</td>
<td>AngII (R)</td>
<td>CATTCTCACAGCGAAACAA</td>
<td></td>
</tr>
<tr>
<td>NM_001289726.1</td>
<td>GAPDH (F)</td>
<td>CTCAATGACCCACAGTCCATGC</td>
<td>201</td>
</tr>
<tr>
<td>NM_001289726.1</td>
<td>GAPDH (R)</td>
<td>CACATTGGGAGGTAGGAACAC</td>
<td></td>
</tr>
</tbody>
</table>

TRPC6, transient receptor potential channel 6; NFAT, nuclear factor of activated T-cells; AngII, angiotensin II; F, forward; R, reverse.

Table II. Biochemical parameters in diabetic rats following 12-week treatment with the angiotensin II receptor blocker, valsartan.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>NC (n=10)</th>
<th>DM (n=10)</th>
<th>ARB (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISI</td>
<td>0.220±0.024</td>
<td>0.05±0.004*</td>
<td>0.06±0.005a</td>
</tr>
<tr>
<td>FINS ng/ml</td>
<td>18.57±1.01</td>
<td>22.09±1.75</td>
<td>20.16±1.57</td>
</tr>
<tr>
<td>FBG mmol/l</td>
<td>5.56±0.64</td>
<td>19.44±0.47*</td>
<td>18.58±0.58*</td>
</tr>
<tr>
<td>HbA1C%</td>
<td>2.84±0.33</td>
<td>6.64±0.45*</td>
<td>6.40±0.72*</td>
</tr>
<tr>
<td>TG mmol/l</td>
<td>1.49±0.15</td>
<td>4.83±0.69*</td>
<td>4.42±0.48*</td>
</tr>
<tr>
<td>TC mmol/l</td>
<td>0.76±0.24</td>
<td>3.99±0.25*</td>
<td>3.78±0.26*</td>
</tr>
<tr>
<td>LDL mmol/l</td>
<td>1.04±0.19</td>
<td>7.38±0.44*</td>
<td>7.07±0.45*</td>
</tr>
<tr>
<td>HDL mmol/l</td>
<td>1.03±0.20</td>
<td>0.50±0.04*</td>
<td>0.52±0.04*</td>
</tr>
<tr>
<td>Scr mmol/l</td>
<td>48.5±7.09</td>
<td>53.7±7.83</td>
<td>50±8.84</td>
</tr>
</tbody>
</table>

*P<0.01 vs. NC. Results are expressed as mean ± standard deviation. ISI, insulin sensitivity index; FINS, fasting serum insulin, FBG: fasting blood glucose; HbA1C, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; Scr, serum creatinine; NC, normal control; DM, rat model of type 2 diabetes mellitus; ARB, angiotensin II receptor blocker (rats with type 2 diabetes treated with angiotensin II receptor blocker, valsartan).
Figure 1. Effect of angiotensin II receptor blocker valsartan on functional parameters of diabetic rats. (A) UAL was elevated in rats with streptozocin-induced DM when compared with NC; however, albumin excretion was decreased in rats treated with the ARB, valsartan. (B) Valsartan also decreased the ratio of KW/BW in diabetic rats, but did not alter the (C) Ccr or (D) SBP. *P<0.01 vs. NC group; #P<0.01 vs. DM group. UAL, urinary albumin level; DM, diabetes mellitus; NC, normal control; ARB, Angiotensin II receptor blocker; KW/BW, kidney weight to body weight; Ccr, creatinine clearance; SBP, systolic blood pressure.

Figure 2. Effect of the ARB valsartan on nephropathy. AngII expression was attenuated in the kidneys of diabetic rats treated with the ARB valsartan when compared with that of untreated DM rats, at the (A) protein and (B) mRNA levels. (C) Valsartan also attenuated glomerular basement membrane thickening and podocyte process effacement. NC rats (n=10) were fed regular rat chow, whereas rats in the DM (n=10) and ARB groups (n=10) were fed a high-calorie diet and injected with streptozocin. The ARB group also received 40 mg/kg/day valsartan once a day for 12 weeks. *P<0.01 vs. NC group; #P<0.01 vs. DM group. AngII, angiotensin II; ARB, angiotensin II receptor blocker; DM, diabetes mellitus; NC, normal control.
TRP channel inhibitor attenuates HG-induced NFAT overexpression in vitro. To further study the role of TRPC6 in this signaling pathway, the present study evaluated the effect of the TRP channel inhibitor SAR7334 on TRPC6 and NFAT expression in cultured podocytes. The results revealed that SAR7334 (the HS group) significantly attenuated the HG-induced increase of AngII, TRPC6 and NFAT expression, at the protein (Fig. 5A-C) and mRNA levels (Fig. 5D-F).

Discussion

Previous studies have reported significantly decreased podocyte numbers and density in patients with diabetic nephropathy, as well as a negative correlation between proteinuria and podocyte injury (37). These investigations contributed greatly to our understanding of the role podocyte injury serves in the glomerular dysfunction of diabetic nephropathy (38,39). Identifying mechanisms underlying these podocyte structural and functional changes may provide novel therapeutic targets for diabetic nephropathy. The present study revealed that treatment with the ARB VAL had no significant effect on systolic blood pressure or creatinine clearance at the administered dose, suggesting that VAL reduced proteinuria by protecting against podocyte injury.

Podocytes in the kidneys as well as in endothelial and distal tubular cells express TRPC6 (40-42). To further explore this phenomenon, the present study measured TRPC6 expression in cultured podocytes. The results revealed the increase in AngII and TRPC6 in the kidneys of diabetic rats and HG-treated podocytes were consistent with those of studies by Durvasula and Shankland (43) and Yoo et al (44) who reported that exposure to HG levels increased AngII and its receptor AngII receptor type 1 in podocytes. Other studies have demonstrated that increased renin secretion and prorenin receptor activity contributed to the activation of the local angiotensin system in a HG environment, driving podocyte injury and loss. In an attempt to further elucidate the mechanisms underlying AngII-induced podocyte injury in diabetic nephropathy, the present study investigated the role of TRPC6 and its substrate NFAT. NFAT is a transcription factor that is predominantly regulated by activation and the subsequent translocation from the cytoplasm to the nucleus. NFAT activation/regulation is measured by total NFAT2 protein/mRNA expression levels (45,46). The results demonstrated that the ARB VAL attenuated the HG-induced increase of TRPC6 and NFAT in podocytes in vivo and in vitro. In addition, changes in albumin excretion and glomerular morphology were ameliorated by ARB treatment. In particular, VAL reversed foot process loss and injury, resulting in a near-normal appearance. This provided further evidence of the role of TRPC6 in AngII-induced podocyte dysfunction. Recent studies have reported
Figure 4. ARB VAL attenuates the HG-induced upregulation of AngII, TRPC6 and NFAT in vitro. Expression of AngII, TRPC6 and NFAT was assessed by (A-C) western blotting and (D-F) reverse transcription-quantitative polymerase chain reaction analysis in podocytes cultured with NG (5.6 mmol/l) or HG (30 mmol/l). Podocytes cultured with NG and HM (25 mmol/l) served as a control for the effects of osmotic pressure. The effect of the ARB was evaluated in podocytes cultured with HG (30 mmol/l) and treated with VAL (10.5 mmol/l). *P<0.05 and **P<0.01 vs. NG group; #P<0.05 vs. HG group. AngII, angiotensin II; ARB, angiotensin II receptor blocker; NG, normal glucose; HG, high glucose; HM, high mannitol; VAL, valsartan; TRPC6, transient receptor potential channel 6; NFAT, nuclear factor of activated T-cells.

Figure 5. TRPC inhibitor SAR7334 attenuates the HG-induced upregulation of TRPC6 and NFAT. Expression of AngII, TRPC6 and NFAT was assessed by (A-C) western blotting and (D-F) reverse transcription-quantitative polymerase chain reaction analysis in podocytes cultured with NG (5.6 mmol/l) or HG (30 mmol/l). Podocytes cultured with NG and HM (25 mmol/l) served as a control for the effects of osmotic pressure. The effects of TRPC inhibition were evaluated in podocytes cultured with HG (30 mmol/l) and treated with SAR7334 (the HS group; 1 µM). *P<0.05 vs. NG group; #P<0.05 vs. HG group. TRPC6, transient receptor potential channel 6; NFAT, nuclear factor of activated T-cells; NG, normal glucose; HG, high glucose; HM, high mannitol; HS, high glucose + the TRP channel inhibitor, SAR7334; AngII, angiotensin II.
that TRPC6 was closely associated with HG-induced apoptosis in cultured podocytes through reactive oxygen species production and the RhoA/Rho-associated protein kinase signaling pathway (15,47). In addition, Li et al (48) described the involvement of the canonical Wnt signaling pathway in diabetic podocyte injury caused by TRPC6 upregulation. However, Liu et al (15) and Yang et al (47) did not confirm their results in vivo. In the present study, a rat model of a high-calorie diet and streptozocin-induced type 2 diabetes was employed to study the role of TRPC6 in podocyte lesions associated with diabetic nephropathy.

Several lines of evidence have suggested that there is a close association between AngII and TRPC6 in non-renal and glomerular cells. For example, TRPC6 has been implicated in AngII-induced vasoconstrictor responses in mesenteric artery myocytes (27). Furthermore, the ARB losartan reversed the effect of AngII on glomerular mesangial cell proliferation by decreasing TRPC6 expression (49). Other cell culture and animal studies demonstrated that AngII had a deleterious effect on podocytes via the upregulation of TRPC6 (32), and that this process required the generation of reactive oxygen species (28). The present results support our hypothesis that TRPC6 is a key mediator of AngII-induced podocyte injury in the progression of type 2 diabetic nephropathy.

To further evaluate the downstream signaling pathway of AngII in podocytes, the present study evaluated the effect of high glucose conditions on the expression of NFAT, a substrate for calcineurin. Other studies have reported that HG levels activated NFAT in vascular smooth muscle and pancreatic β-cells (50,51). Furthermore, NFAT activation was involved in podocyte injury and glomerulosclerosis, and NFAT mediated HG-induced glomerular podocyte apoptosis through the upregulation of B-cell lymphoma 2-associated X protein (Bax) (31,52,53). Zhang et al (54) recently demonstrated that an NFAT inhibitor exerted renoprotective effects in diabetic db/db rats by attenuating HG-induced podocyte apoptosis.

The present study revealed that HG-induced NFAT levels were attenuated by treatment with the TRPC6 channel inhibitor SAR7334 in podocytes, suggesting that hyperglycemia activated TRPC6 channels via increased AngII expression. The augmented Ca\(^{2+}\) influx caused the activation of NFAT, mediating podocyte apoptosis by increasing Bax expression, leading to glomerular filtration barrier dysfunction.

In conclusion, the results of the present study suggest that the AngII/TRPC6/NFAT axis may mediate podocyte injury in the early progression of type 2 diabetic nephropathy. In addition, TRPC6 may represent a novel therapeutic target for diabetic nephropathy.

Acknowledgements

The authors would like to thank Professor Liqiu Liu (Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, China) for providing the conditionally immortalized mouse podocyte cell line used in the present study, as well as Professor Donghui Zhen (Department of Pathology, Qilu Hospital of Shandong University, Qingdao, China) for assisting with electron microscopy.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

RM designed and coordinated the present study, and performed the experiments. RM, YX, HZ, DZ, DY, LS and YL analyzed the data. RM, LS and YL wrote the paper.

Ethics approval and consent to participate

Protocols for the animal experiments were approved by the Qingdao University Animal Care and Use Committee (Qingdao, China) and were developed in accordance with guidelines set by the National Institutes of Health Guide for Care and Use of Laboratory Animals. The present study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


